Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Announces Quarterly Earnings Results

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.62 by $0.09, Zacks reports. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 17.72%.

Swedish Orphan Biovitrum Stock Performance

BIOVF opened at $45.72 on Tuesday. The firm has a market cap of $16.27 billion, a PE ratio of 21.67 and a beta of 0.47. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The business has a fifty day simple moving average of $46.31 and a 200-day simple moving average of $43.98. Swedish Orphan Biovitrum has a fifty-two week low of $34.88 and a fifty-two week high of $49.03.

Wall Street Analyst Weigh In

BIOVF has been the subject of several research reports. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Nordea Equity Research downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

View Our Latest Analysis on BIOVF

Swedish Orphan Biovitrum Company Profile

(Get Free Report)

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.

Read More

• Five stocks we like better than Swedish Orphan Biovitrum
• GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
• A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
• Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
• Comfort Systems Earnings: AI Slowdown or More Growth Ahead?

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.